KalVista Pharmaceuticals to Host Financial Results Conference Call
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy KALV?
Source: Newsfilter
- Conference Call Announcement: KalVista Pharmaceuticals will host a conference call on March 25, 2026, at 8:30 a.m. ET to review its eight-month fiscal year 2025 financial results and provide a corporate update, aiming to enhance investor understanding of the company's financial health.
- Webcast Accessibility: The live audio webcast will be accessible on the Investors section of the company's website, ensuring that global investors can receive real-time information, thereby increasing transparency and boosting market confidence.
- Product Innovation Context: KalVista is dedicated to delivering life-changing therapies for rare disease patients, with EKTERLY® being the first and only oral on-demand treatment for hereditary angioedema, showcasing the company's innovative capabilities and market potential in this niche area.
- Global Community Collaboration: KalVista works closely with the global hereditary angioedema community to improve treatment and care for this disease, reflecting the company's commitment to addressing patient needs and fulfilling its social responsibility.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KALV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KALV
Wall Street analysts forecast KALV stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.820
Low
29.00
Averages
34.38
High
39.00
Current: 16.820
Low
29.00
Averages
34.38
High
39.00
About KALV
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
KalVista Pharmaceuticals to Host Financial Results Conference Call
- Conference Call Announcement: KalVista Pharmaceuticals will host a conference call on March 25, 2026, at 8:30 a.m. ET to review its eight-month fiscal year 2025 financial results and provide a corporate update, aiming to enhance investor understanding of the company's financial health.
- Webcast Accessibility: The live audio webcast will be accessible on the Investors section of the company's website, ensuring that global investors can receive real-time information, thereby increasing transparency and boosting market confidence.
- Product Innovation Context: KalVista is dedicated to delivering life-changing therapies for rare disease patients, with EKTERLY® being the first and only oral on-demand treatment for hereditary angioedema, showcasing the company's innovative capabilities and market potential in this niche area.
- Global Community Collaboration: KalVista works closely with the global hereditary angioedema community to improve treatment and care for this disease, reflecting the company's commitment to addressing patient needs and fulfilling its social responsibility.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting strong confidence in the company.
- Asset Management Proportion: Savara's shares account for 4.1% of VR Adviser's over $2 billion in assets under management, indicating its significance in the firm's portfolio and potential influence on future investment decisions.
- Market Potential: Savara focuses on developing inhaled biologics for rare respiratory diseases, and although it currently lacks approved products, its lead candidate, molgramostim, is in late-stage trials and aims to address significant unmet medical needs, suggesting long-term market potential.
- Investment Risks: While Savara's stock surged 96.4% last year, investors should be aware of the high-risk nature of the biotech industry, as Savara has no revenue-generating products, making its future stock performance heavily reliant on regulatory approvals and potential revenue from its lead drug candidate.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting confidence in Savara's future performance.
- AUM Proportion: Savara represents 4.1% of VR Adviser's total assets under management, highlighting its strategic significance among the firm's 27 positions and indicating a strong belief in the company's potential.
- Market Performance: Savara's stock gained 96.4% in 2022, leading investors to maintain an optimistic outlook for continued growth, particularly with expectations for 2025's performance.
- Risk Advisory: While Savara shows promise in the biotech sector, the lack of approved products and current revenue generation necessitates caution from investors due to the inherent high-risk nature of the investment.
See More
Needham Raises Kalvista Price Target to $35
- Price Target Increase: Needham raised the price target for Kalvista Pharmaceuticals Inc from $32 to $35, with analyst Serge Belanger maintaining a Buy rating, reflecting confidence in the company's future growth prospects.
- Market Performance: Kalvista shares closed at $15.82 on Thursday, indicating that despite the target price increase, the current stock price remains significantly below the new target, suggesting a potential undervaluation by the market.
- Competitive Analysis: In the biopharmaceutical sector, Kalvista's advancements in innovative drug development may attract increased investor interest, especially in light of the target price increase, which could stimulate stock price appreciation.
- Investor Confidence: The positive rating and target price increase from analysts may bolster investor confidence in Kalvista, potentially facilitating its future financing and market expansion plans.
See More
KalVista Launches EKTERLY, Achieves $35M in First-Year Revenue
- Positive Market Response: KalVista Pharmaceuticals reported approximately $35 million in net product revenue for its hereditary angioedema treatment EKTERLY in Q4 2025, indicating strong market demand through growing prescriber adoption and repeat prescriptions.
- Breakthrough Treatment: EKTERLY is the first and only oral on-demand treatment approved by the FDA in July 2025 for acute attacks in patients aged 12 and older, representing a significant advancement in the treatment landscape.
- Global Expansion Plans: KalVista granted Multicare Pharmaceuticals exclusive rights to commercialize sebetralstat in Latin America, covering Brazil, Argentina, Colombia, and Mexico, thereby enhancing its global market reach.
- Rapid Clinical Progress: The company completed enrollment in the Phase 3 KONFIDENT-KID trial evaluating sebetralstat in children aged 2 to 11 a full year ahead of schedule, with plans to submit a new drug application in Q3 2026 and a potential U.S. launch in 2027.
See More
Greenbrier Companies Inc Beats Q1 Earnings Estimates with $1.14 EPS and $706.1M Sales
- Earnings Beat: Greenbrier Companies Inc reported a Q1 earnings per share of $1.14, surpassing market expectations of $0.87, indicating strong performance that may boost investor confidence.
- Sales Surge: The company's quarterly sales reached $706.1 million, significantly exceeding the anticipated $626.297 million, demonstrating robust product demand that could enhance market share and competitiveness.
- Stock Fluctuation: Despite the positive earnings report, Greenbrier's stock fell 0.8% to $52.90 in after-hours trading, reflecting market concerns about the broader economic environment.
- Industry Impact: Greenbrier's strong financial results may positively influence the transportation and logistics sector, attracting more investor attention to related stocks and potentially driving overall industry recovery.
See More
KalVista Pharmaceuticals to Host Financial Results Conference Call
- Conference Call Announcement: KalVista Pharmaceuticals will host a conference call on March 25, 2026, at 8:30 a.m. ET to review its eight-month fiscal year 2025 financial results and provide a corporate update, aiming to enhance investor understanding of the company's financial health.
- Webcast Accessibility: The live audio webcast will be accessible on the Investors section of the company's website, ensuring that global investors can receive real-time information, thereby increasing transparency and boosting market confidence.
- Product Innovation Context: KalVista is dedicated to delivering life-changing therapies for rare disease patients, with EKTERLY® being the first and only oral on-demand treatment for hereditary angioedema, showcasing the company's innovative capabilities and market potential in this niche area.
- Global Community Collaboration: KalVista works closely with the global hereditary angioedema community to improve treatment and care for this disease, reflecting the company's commitment to addressing patient needs and fulfilling its social responsibility.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting strong confidence in the company.
- Asset Management Proportion: Savara's shares account for 4.1% of VR Adviser's over $2 billion in assets under management, indicating its significance in the firm's portfolio and potential influence on future investment decisions.
- Market Potential: Savara focuses on developing inhaled biologics for rare respiratory diseases, and although it currently lacks approved products, its lead candidate, molgramostim, is in late-stage trials and aims to address significant unmet medical needs, suggesting long-term market potential.
- Investment Risks: While Savara's stock surged 96.4% last year, investors should be aware of the high-risk nature of the biotech industry, as Savara has no revenue-generating products, making its future stock performance heavily reliant on regulatory approvals and potential revenue from its lead drug candidate.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting confidence in Savara's future performance.
- AUM Proportion: Savara represents 4.1% of VR Adviser's total assets under management, highlighting its strategic significance among the firm's 27 positions and indicating a strong belief in the company's potential.
- Market Performance: Savara's stock gained 96.4% in 2022, leading investors to maintain an optimistic outlook for continued growth, particularly with expectations for 2025's performance.
- Risk Advisory: While Savara shows promise in the biotech sector, the lack of approved products and current revenue generation necessitates caution from investors due to the inherent high-risk nature of the investment.
See More
Needham Raises Kalvista Price Target to $35
- Price Target Increase: Needham raised the price target for Kalvista Pharmaceuticals Inc from $32 to $35, with analyst Serge Belanger maintaining a Buy rating, reflecting confidence in the company's future growth prospects.
- Market Performance: Kalvista shares closed at $15.82 on Thursday, indicating that despite the target price increase, the current stock price remains significantly below the new target, suggesting a potential undervaluation by the market.
- Competitive Analysis: In the biopharmaceutical sector, Kalvista's advancements in innovative drug development may attract increased investor interest, especially in light of the target price increase, which could stimulate stock price appreciation.
- Investor Confidence: The positive rating and target price increase from analysts may bolster investor confidence in Kalvista, potentially facilitating its future financing and market expansion plans.
See More
KalVista Launches EKTERLY, Achieves $35M in First-Year Revenue
- Positive Market Response: KalVista Pharmaceuticals reported approximately $35 million in net product revenue for its hereditary angioedema treatment EKTERLY in Q4 2025, indicating strong market demand through growing prescriber adoption and repeat prescriptions.
- Breakthrough Treatment: EKTERLY is the first and only oral on-demand treatment approved by the FDA in July 2025 for acute attacks in patients aged 12 and older, representing a significant advancement in the treatment landscape.
- Global Expansion Plans: KalVista granted Multicare Pharmaceuticals exclusive rights to commercialize sebetralstat in Latin America, covering Brazil, Argentina, Colombia, and Mexico, thereby enhancing its global market reach.
- Rapid Clinical Progress: The company completed enrollment in the Phase 3 KONFIDENT-KID trial evaluating sebetralstat in children aged 2 to 11 a full year ahead of schedule, with plans to submit a new drug application in Q3 2026 and a potential U.S. launch in 2027.
See More
Greenbrier Companies Inc Beats Q1 Earnings Estimates with $1.14 EPS and $706.1M Sales
- Earnings Beat: Greenbrier Companies Inc reported a Q1 earnings per share of $1.14, surpassing market expectations of $0.87, indicating strong performance that may boost investor confidence.
- Sales Surge: The company's quarterly sales reached $706.1 million, significantly exceeding the anticipated $626.297 million, demonstrating robust product demand that could enhance market share and competitiveness.
- Stock Fluctuation: Despite the positive earnings report, Greenbrier's stock fell 0.8% to $52.90 in after-hours trading, reflecting market concerns about the broader economic environment.
- Industry Impact: Greenbrier's strong financial results may positively influence the transportation and logistics sector, attracting more investor attention to related stocks and potentially driving overall industry recovery.
See More
